Key Differences Between Wegovy and Mounjaro Available Now
Wegovy or Mounjaro Which Is Better: UK Stock Availability Comparison
When deciding between Wegovy or Mounjaro, availability has been a crucial factor for UK patients. EverydayMeds maintains consistent stock levels of both treatments, with all five Wegovy doses (0.25mg through 2.4mg) and the complete Mounjaro range ready for immediate dispatch. Unlike supply shortages experienced historically, our direct relationship with Novo Nordisk ensures reliable Wegovy availability, whilst our Mounjaro stock comes directly from Eli Lilly's UK distribution network.
The question of Wegovy or Mounjaro which is better often comes down to individual response and practical considerations. Both are prescription-only medicines requiring clinical assessment through our 3-minute online evaluation. Our prescribers typically receive approval decisions within 3 working days (or 24 hours with express service), meaning you can start treatment this week rather than joining lengthy NHS waiting lists. Temperature-controlled next-day delivery ensures both medications arrive in optimal condition for immediate use.
Pricing Comparison: Wegovy vs Mounjaro Value Analysis
Wegovy pricing starts at £79.99 for the 0.25mg starter dose (after FIRST40 discount applied at checkout), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, providing your first 8 weeks of treatment in a single order. Returning customers benefit from the DOSE25 discount code applied at checkout for ongoing savings.
When comparing Wegovy or Mounjaro which is better from a cost perspective, both follow similar dose escalation protocols requiring multiple pen strengths. Mounjaro pricing mirrors the pharmaceutical industry standard for GLP-1 class medications, though specific costs vary by dose strength. The convenience factor of our bundle options—such as the Intro Trio (0.25mg, 0.5mg & 1mg) at £299.99—eliminates multiple ordering cycles and ensures uninterrupted treatment progression during your first 12 weeks.
Clinical Evidence: Understanding Trial Results for Both Treatments
In clinical trials, patients taking Wegovy alongside diet and exercise experienced approximately 15% average weight loss at 68 weeks in the STEP 1 study (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent results across different patient populations, with STEP 2 showing 9.6% average weight loss in patients with type 2 diabetes. These results reflect Wegovy's mechanism as a GLP-1 receptor agonist working on brain appetite centres.
Mounjaro's SURMOUNT trials evaluated tirzepatide's dual GIP+GLP-1 mechanism in weight management settings. When considering Wegovy or Mounjaro which is better based on clinical evidence, both medications demonstrated significant weight reduction compared to placebo in their respective studies. However, direct head-to-head comparisons aren't available due to different trial designs, populations, and endpoints, making individual clinical assessment essential for determining the most appropriate choice.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone released after eating. This medication works primarily on the hypothalamus—your brain's appetite control centre—to reduce hunger signals and promote earlier satiety during meals. The once-weekly injection maintains steady semaglutide levels, providing consistent appetite suppression throughout the week. Unlike stimulant-based weight management approaches, Wegovy works with your body's existing hormone pathways to naturally reduce caloric intake. Most patients notice decreased food cravings and feeling satisfied with smaller portions within the first few weeks of treatment. The medication requires alongside implementation of a reduced-calorie diet and increased physical activity for optimal effectiveness.
Streamlined Ordering Process for Both Medications
Starting treatment involves a comprehensive 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review every application thoroughly, typically providing decisions within 3 working days (or 24 hours with express review service). Once approved, both Wegovy and Mounjaro ship via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. The secure packaging includes cooling packs and temperature monitoring to ensure your prescription-only medicine arrives in perfect condition. Payment processing occurs only after prescriber approval, with discount codes FIRST40 (new customers) or DOSE25 (returning customers) applied automatically at checkout to reach the advertised prices.
Storage and Practical Usage Considerations
Both medications require refrigeration at 2-8°C before first use, but Wegovy offers superior travel flexibility with 6 weeks room temperature stability (below 30°C) once removed from the fridge. Mounjaro provides 21 days room temperature storage, making Wegovy more suitable for extended travel or irregular schedules. Both use pre-filled FlexTouch pen systems with hidden needles for comfortable self-injection. Dose escalation follows structured protocols—starting low and gradually increasing every 4 weeks to minimise potential side effects. The progression from starter doses to maintenance levels typically takes 16 weeks for Wegovy, requiring coordination of different pen strengths throughout your initial treatment phase.
Wegovy or Mounjaro Which Is Better: Mechanism Comparison for UK Patients
The fundamental difference lies in hormone targeting: Wegovy activates GLP-1 receptors exclusively, whilst Mounjaro targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism may provide additional metabolic benefits beyond appetite suppression, though individual response varies significantly between patients. Both medications work on brain appetite centres, but the dual-hormone approach theoretically offers more comprehensive metabolic regulation.
UK patients often ask Wegovy or Mounjaro which is better for their specific circumstances, but the answer depends on individual medical history, tolerance, and response patterns. Some patients respond optimally to single-hormone GLP-1 stimulation, whilst others benefit from dual-hormone targeting. Our clinical team evaluates factors including diabetes status, cardiovascular history, and previous weight management attempts to guide medication selection. Both treatments are available immediately from our GPhC-registered pharmacy #9012878, ensuring you can start with either option based on clinical recommendation.
Complete Treatment Access Without NHS Delays
Rather than debating Wegovy or Mounjaro which is better in theory, EverydayMeds provides immediate access to both options with full prescriber support for individual optimisation. Our bundle pricing eliminates supply interruptions—the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 covers weeks 5-16 of treatment progression. Express prescriber review ensures treatment starts within 48 hours of application submission for eligible patients. Apply discount code FIRST40 at checkout for new customer savings, or DOSE25 for returning patient discounts on subsequent orders. Both medications represent proven pharmaceutical innovation for sustainable weight management, requiring only your commitment to comprehensive lifestyle changes alongside medical therapy. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today and receive expert guidance on the most appropriate treatment choice for your individual circumstances.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
